US2134246A - Stable solutions of ascorbic acid salts of histidine and process for the manufacture of same - Google Patents

Stable solutions of ascorbic acid salts of histidine and process for the manufacture of same Download PDF

Info

Publication number
US2134246A
US2134246A US149548A US14954837A US2134246A US 2134246 A US2134246 A US 2134246A US 149548 A US149548 A US 149548A US 14954837 A US14954837 A US 14954837A US 2134246 A US2134246 A US 2134246A
Authority
US
United States
Prior art keywords
histidine
ascorbic acid
acid salts
manufacture
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US149548A
Inventor
Elger Franz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of US2134246A publication Critical patent/US2134246A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • Example 1 310 parts by weight of histidine base and 1'76 parts by weight of ascorbic acid are dissolved in 5,000 parts of water through which a current 01' nitrogen is continuously passed, the water having previously been boiled to remove air and cooled in a current of nitrogen.
  • the finished solution can, for instance, be filled into ampoules containing nitrogen which are immediately sealed. These solutions remain permanently colorless. They may even be heated (sterilized) in a current ofsteam without any appreciable change of color.
  • Example '2 209.5 parts'by weight of histidine mono-hydrochloride (containing 1 mol. of water of crystallization) and 199 parts by weight of sodium ascorbate are dissolved in 5,000 parts of water free from oxygen, nitrogen being introduced during dissolution. The air is removed from the containers in which the solution is to be stored by evacuation. The solutions remain colorless.
  • a package comprising a solution of the ascorbic acid salts of histidine in oxygen free I water in a container excluding oxygen.
  • a package comprising a solution of the ascorbic acid salts of histidine in water containing gases free from oxygen in a container excluding oxygen.
  • a package comprising a solution ofthe ascorbic acid salts of histidine in water free from oxygen under nitrogen in a container excluding 6.
  • a process for the manufacture of stable solutions of the ascorbic acid salts of histidine which comprises preparing a solution of said salts in oxygen free water and packaging said solutio in containers under nitrogen.

Description

Patented Oct. 25, 1938 UNITED STATES STABLE SOLUTIONS OF ASCORBIC ACID SALTS OF HISTIDINE AND PROCESS FOR THE MANUFACTURE OF SAME Franz Elger, Basel, Switzerland, assignor to Hollmann-La Roche Inc., Nutley, N. J., a corporation of New Jersey No Drawing.
Application June 21, 1937, Serial No. 149,548. In Switzerland July 9, 1936 6 Claims.
If ascorbic acid is neutralized with histidine base, the solutions of the resulting salts are not stable as is evident from the fact that they soon turn raspberry-red to dark orange-brown. If,
for instance, 3.1 grammes of histidine base W mol.) and 1.76 grammes of ascorbic acid mol.) are dissolved in 100 com. of water, the resulting solution of the salt has a pHof 6.0. It very rapidly changes color, first light pink,
10 then to raspberry-red, and finally becomes dark orange-brown. Solutions of other ascorbic acid salts, for instance of sodium ascorbate, or of other histidine salts, such as histidine hydrochloride, having the same pH, do not show this rapid change of color. This is a'property peculiar to the solutions of ascorbic acid salts of histidine. The constitution of the resulting colored compounds has not yet been ascertained.
This change of color can be completely inhibited if the utmost care is taken to prevent access of air during the preparation of the solutions of ascorbic acid salts of histidine and also to protect the finished solutions against access of air. This can be achieved, for instance, by dissolving ascorbic acid and histidine base. or ascorbates and salts of histidine, in the required proportions in water through which, for instance, carbon dioxide or nitrogen has been passed for some time, and preventing access of air to the solutions so prepared, which can be efiected by filling the containers with a gas free from oxygen, or by removing the air therefrom by evacuation.
The stable solutions of the. ascorbic acid salts of histidine are to be used in the treatment of gastroduodenal ulcers by injection. Both the histidine and the ascorbic acid radicals have proven valuable in the treatment of such ulcers as evidenced by the articles of I. F. Volina and R. F. McLaughlin in The Medical Record, New
York City, April 17, 1935. and in the Illinois Medical Journal, January 1936, and the article of P. B. Davidson in Journal of the American Medical Association, vol. 90, page 1014, and the article of Scale Harris, Journal American Medical Association," vol. 91, page 1452.
Example 1 310 parts by weight of histidine base and 1'76 parts by weight of ascorbic acid are dissolved in 5,000 parts of water through which a current 01' nitrogen is continuously passed, the water having previously been boiled to remove air and cooled in a current of nitrogen. The finished solution can, for instance, be filled into ampoules containing nitrogen which are immediately sealed. These solutions remain permanently colorless. They may even be heated (sterilized) in a current ofsteam without any appreciable change of color.
Example '2 209.5 parts'by weight of histidine mono-hydrochloride (containing 1 mol. of water of crystallization) and 199 parts by weight of sodium ascorbate are dissolved in 5,000 parts of water free from oxygen, nitrogen being introduced during dissolution. The air is removed from the containers in which the solution is to be stored by evacuation. The solutions remain colorless.
I claim:
1. A package comprising a solution of the ascorbic acid salts of histidine in oxygen free I water in a container excluding oxygen.
2. A package comprising a solution of the ascorbic acid salts of histidine in water containing gases free from oxygen in a container excluding oxygen.
A package comprising a solution ofthe ascorbic acid salts of histidine in water free from oxygen under nitrogen in a container excluding 6. A process for the manufacture of stable solutions of the ascorbic acid salts of histidine which comprises preparing a solution of said salts in oxygen free water and packaging said solutio in containers under nitrogen.
FRANZ ELGER.
US149548A 1936-07-09 1937-06-21 Stable solutions of ascorbic acid salts of histidine and process for the manufacture of same Expired - Lifetime US2134246A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2134246X 1936-07-09

Publications (1)

Publication Number Publication Date
US2134246A true US2134246A (en) 1938-10-25

Family

ID=4567641

Family Applications (1)

Application Number Title Priority Date Filing Date
US149548A Expired - Lifetime US2134246A (en) 1936-07-09 1937-06-21 Stable solutions of ascorbic acid salts of histidine and process for the manufacture of same

Country Status (1)

Country Link
US (1) US2134246A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2419230A (en) * 1942-09-07 1947-04-22 Frances R Ruskin Therapeutic compositions and method of preparing same
US2498778A (en) * 1947-11-10 1950-02-28 Organic Chemicals Inc Composition to increase the absorption by the body of histamine
US2539483A (en) * 1945-03-28 1951-01-30 Simon L Ruskin Urea ascorbate and complexes containing the same and process for their manufacture
US2570734A (en) * 1948-12-30 1951-10-09 Interchem Corp Stable histidine ascorbate
US2606903A (en) * 1944-03-29 1952-08-12 Physiological Chemicals Compan Ascorbic acid addition compound of sulfathiazole
US3056491A (en) * 1958-08-29 1962-10-02 Polaroid Corp Fluid containers
US3132154A (en) * 1953-12-07 1964-05-05 Meyer-Doring Hans Production of ascorbic acid esters
US3173580A (en) * 1962-09-21 1965-03-16 Polaroid Corp Fluid containers
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US6020367A (en) * 1997-12-02 2000-02-01 Avon Products, Inc. Supersaturated ascorbic acid solutions
US20050154054A1 (en) * 2004-01-13 2005-07-14 Skinceuticals, Inc. Stabilized ascorbic acid compositions and methods therefor
US20090286874A1 (en) * 2006-03-22 2009-11-19 L'oreal Anti-aging composition containing phloretin

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2419230A (en) * 1942-09-07 1947-04-22 Frances R Ruskin Therapeutic compositions and method of preparing same
US2606903A (en) * 1944-03-29 1952-08-12 Physiological Chemicals Compan Ascorbic acid addition compound of sulfathiazole
US2539483A (en) * 1945-03-28 1951-01-30 Simon L Ruskin Urea ascorbate and complexes containing the same and process for their manufacture
US2498778A (en) * 1947-11-10 1950-02-28 Organic Chemicals Inc Composition to increase the absorption by the body of histamine
US2570734A (en) * 1948-12-30 1951-10-09 Interchem Corp Stable histidine ascorbate
US3132154A (en) * 1953-12-07 1964-05-05 Meyer-Doring Hans Production of ascorbic acid esters
US3056491A (en) * 1958-08-29 1962-10-02 Polaroid Corp Fluid containers
US3173580A (en) * 1962-09-21 1965-03-16 Polaroid Corp Fluid containers
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US6020367A (en) * 1997-12-02 2000-02-01 Avon Products, Inc. Supersaturated ascorbic acid solutions
US20050154054A1 (en) * 2004-01-13 2005-07-14 Skinceuticals, Inc. Stabilized ascorbic acid compositions and methods therefor
US7179841B2 (en) 2004-01-13 2007-02-20 L'oreal Usa Creative, Inc. Stabilized ascorbic acid compositions and methods therefor
US20090286874A1 (en) * 2006-03-22 2009-11-19 L'oreal Anti-aging composition containing phloretin
US9248082B2 (en) 2006-03-22 2016-02-02 L'oreal Anti-aging composition containing phloretin

Similar Documents

Publication Publication Date Title
US2134246A (en) Stable solutions of ascorbic acid salts of histidine and process for the manufacture of same
NO171765B (en) PROCEDURE FOR PREPARING SOLUTIONS OF Lactic Acid Salts of PIPERAZINYLKINOLONE AND PIPERAZINYLAZAKINOLONCARBOXYL ACIDS
SK10982002A3 (en) Pharmaceutical composition comprising pemetrexed together with monothioglycerol L-cystein or thioglycolic acid
US2187467A (en) Cevitamate solution
EP0278674B1 (en) Sterilization of compositions of limited stability
JP3243387B2 (en) Plastic container containing bicarbonate-containing chemicals
US3035973A (en) Gelatin capsule containing calcium dioctyl sulfosuccinate
DE69115011D1 (en) STABLE HEMOGLOBIN-BASED AGENT AND METHOD FOR THEIR STORAGE.
US4073907A (en) Stabilized aminophylline solution and process therefor
NO156675B (en) PROCEDURE FOR PREPARING A STABLE, CONCENTRATED CISPLATIN SOLUTION.
US2266992A (en) Therapeutic composition
US2694487A (en) Flexibility of catgut sutures
SU1025680A1 (en) Method for preparing galss products for packing medical preparations
JPS60239414A (en) Method for suppressing discoloration of etoposide solution
US2358331A (en) Parenteral solutions of 9-polyhydroxyalkyl-iso-alloxazines
US2647853A (en) Injectable solution of salt of para-aminosalicylic acid
JP2010532349A (en) Stabilized ophthalmic solution
US3239420A (en) Gelatin composition
US4460573A (en) Methods of stabilizing thimerosal in presence of polyvinylpyrrolidone
US3597456A (en) Method for preparing sterile lecithin
US2260004A (en) Stable soluble magnesium acid citrate
US2063297A (en) Acid hardening fixing composition and method of preparing the same
FI58072C (en) FOERFARANDE FOER FRAMSTAELLNING AV ETT TORRPREPARAT AV ETT ALKALIMETALLSALT AV DEHYDROEPIANDROSTERONSULFAT FOER PARENTERAL ADMINISTRATION
JPS6185314A (en) Non-oral administration composition
DE718991C (en) Process for the production of durable solutions of ascorbic acid salts of histidine